Prostatic Cancer Versus Androgen Deficiency (AndroCan)
Localised Cancer of Prostate and Androgen Deficiency.
Sponsor: Hopital Foch
A NA clinical study on Cancer of Prostate, this trial is completed. The trial is conducted by Hopital Foch and has accumulated 10 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Feb 2022 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Dec 2021 — Feb 2022 [monthly]
Active Not Recruiting NA
-
Feb 2021 — Dec 2021 [monthly]
Active Not Recruiting NA
▶ Show 5 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting NA
-
Nov 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Nov 2018 — Nov 2019 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hopital Foch
For direct contact, visit the study record on ClinicalTrials.gov .